A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation safeguards at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can vary from causing mild cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine works by activating the mother’s body’s defences to produce defence proteins, which are then passed to the developing baby through the placenta. This maternal immunity offers newborns with instant defence from the moment of birth, precisely when they are most vulnerable to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is given four weeks or more before delivery. Even briefer gaps between vaccination and birth can still provide meaningful protection, with evidence suggesting that a two-week gap is adequate to shield babies born slightly early. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst observing that protection can still occur even if administered later in the third trimester.
- Nearly 85% coverage when immunised four weeks before birth
- Antibodies from the mother passed through the placenta protect newborns from birth
- Protection achievable with two-week gap before early delivery
- Vaccination in the third trimester still provides meaningful infant protection
Strong evidence from the latest research
The efficacy of the pregnancy RSV vaccine has been demonstrated through a extensive research programme undertaken in England, reviewing data from close to 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90% of all births during that six-month period, providing strong and reliable evidence of the vaccine’s practical effectiveness. The study’s findings have been supported by the UK Health Security Agency as showing “excellent protection” for newborns during their most vulnerable early months. The breadth of this investigation offers healthcare professionals and prospective parents with trust in the vaccine’s proven efficacy across varied populations and settings.
The results reveal a notable picture of the vaccine’s protective power. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the great majority being infants whose mothers had not received the vaccination. This marked difference emphasises the vaccine’s vital importance in preventing serious illness in newborns. The drop in hospital admissions surpassing 80 per cent represents a substantial public health milestone, helping to prevent thousands of infants from experiencing the alarming and potentially severe symptoms linked to severe RSV infection. These findings strengthen the importance of the vaccination programme introduced in the UK in 2024.
Study methodology and scope
The research reviewed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish direct comparisons of RSV infection rates and hospitalisations. The large sample size and comprehensive nature of the data collection ensured that findings were statistically robust and reflective of the wider population, rather than isolated cases or small subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at differing periods before delivery. This allowed researchers to determine the shortest interval needed between vaccination and birth for best possible protection, as well as to determine whether protection continued to be effective with shorter intervals. The methodology captured practical outcomes rather than laboratory-based settings, providing practical evidence of how the vaccine performs when delivered across different clinical contexts and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and its hazards
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity changing substantially from mild cold-like symptoms to severe, life-threatening chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.
The infection triggers deep inflammation in the lungs and airways, making it perilously hard for infected babies to feed and breathe adequately. Parents frequently observe their babies visibly struggling, their chests rising whilst they try to pull adequate oxygen into their weakened respiratory system. Whilst most infants improve through supportive care, a modest yet notable proportion perish from RSV-related complications each year, making vaccination as prevention a essential public health objective for safeguarding the youngest and most at-risk people in our communities.
- RSV triggers inflammation in lungs, leading to serious respiratory problems in babies
- Approximately half of newborns catch the infection in their first few months of life
- Symptoms range from mild colds to serious chest infections that threaten life needing hospital treatment
- More than 20,000 UK infants require serious hospital care for RSV each year
- A small number of infants succumb to RSV related complications each year in the UK
Take-up rates and expert recommendations
Since the RSV vaccine programme began in 2024, health officials have highlighted the significance of pregnant women getting their jab at the ideal time for greatest protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has underscored that timing is crucial for ensuring newborns receive the strongest possible immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery offers nearly 85% protection, experts advise women to receive their vaccine as early as possible from 28 weeks of pregnancy forward to increase the antibodies passed to their babies via the placenta.
The communication from public health bodies remains clear: pregnant women ought to prioritise vaccination during their third trimester, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has reassured expectant mothers that protection remains still achievable with reduced timeframes between vaccination and birth, including even a two-week gap for those giving birth ahead of schedule. This adaptable strategy recognises the realities of pregnancy and childbirth whilst maintaining strong protection for at-risk infants during their most critical early months when RSV represents the highest danger of serious illness.
Regional disparities in vaccine uptake
Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Certain regions have attained greater immunisation rates among qualifying expectant mothers, whilst others continue working to increase awareness and availability of the jab. These geographical variations demonstrate differences across healthcare infrastructure, communication strategies, and local engagement efforts, though the overall statistics shows consistently strong protection regardless of geographical location.
- NHS trusts rolling out multiple messaging strategies to reach pregnant women
- Regional disparities in immunisation take-up in different parts of England require targeted improvement
- Local healthcare systems adapting programmes to align with local requirements and situations
Real-world impact and parental perspectives
The vaccine’s remarkable effectiveness translates into concrete gains for families throughout the United Kingdom. With over 20,000 babies hospitalised annually due to RSV before the launch of this protective measure, the 80% decrease in admissions equates to thousands of infants spared from critical disease. Parents no more face the troubling prospect of watching their newborns gasping for air or difficulty feeding, symptoms that characterise critical RSV illness. The vaccine has substantially transformed the terrain of neonatal respiratory health, giving expectant mothers a proactive tool to protect their most at-risk babies during those crucial first weeks.
For families like that of Malachi, whose serious RSV infection resulted in profound brain damage, the vaccine’s availability carries deep personal significance. His mother’s promotion of the jab highlights the life-altering consequences that treatable infection can inflict on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such serious complications—hospital stay, oxygen dependency, neurological damage—are now largely avoidable has provided considerable reassurance to pregnant women navigating their late pregnancy, converting what was once an inevitable seasonal threat into a manageable health risk.